Theravance Biopharma Toekomstige groei
Future criteriumcontroles 4/6
Theravance Biopharma is forecast to grow earnings and revenue by 57.2% and 18.9% per annum respectively while EPS is expected to grow by 57.4% per annum.
Belangrijke informatie
57.2%
Groei van de winst
57.4%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 23.7% |
| Inkomstengroei | 18.9% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 06 Aug 2024 |
Recente toekomstige groei-updates
Recent updates
We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow
Jul 16
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now
May 02Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S
Feb 05Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts
Nov 11Theravance to purchase $95M of ordinary shares
Sep 28Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade
Sep 21Theravance Biopharma announces $250M capital return program
Sep 19Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M
Aug 04Theravance: All-Round Failure
Mar 10Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%
Aug 09Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study
Jun 21Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year
May 09Theravance Biopharma EPS misses by $0.16, misses on revenue
May 04Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 118 | 17 | 108 | N/A | 5 |
| 12/31/2025 | 96 | 3 | 5 | N/A | 5 |
| 12/31/2024 | 71 | -36 | -12 | N/A | 5 |
| 6/30/2024 | 62 | -46 | -10 | -9 | N/A |
| 3/31/2024 | 62 | -45 | -18 | -17 | N/A |
| 12/31/2023 | 57 | -55 | -29 | -27 | N/A |
| 9/30/2023 | 55 | -61 | -152 | -150 | N/A |
| 6/30/2023 | 51 | -68 | -172 | -170 | N/A |
| 3/31/2023 | 49 | -75 | -173 | -172 | N/A |
| 12/31/2022 | 51 | -93 | -188 | -187 | N/A |
| 9/30/2022 | 52 | -136 | -106 | -105 | N/A |
| 6/30/2022 | 52 | -196 | -131 | -129 | N/A |
| 3/31/2022 | 54 | -226 | -166 | -164 | N/A |
| 12/31/2021 | 55 | -265 | -211 | -208 | N/A |
| 9/30/2021 | 59 | -266 | -235 | -230 | N/A |
| 6/30/2021 | 64 | -264 | -267 | -262 | N/A |
| 3/31/2021 | 66 | -275 | -273 | -265 | N/A |
| 12/31/2020 | 72 | -295 | -257 | -250 | N/A |
| 9/30/2020 | 83 | -285 | -257 | -250 | N/A |
| 6/30/2020 | 77 | -270 | -222 | -217 | N/A |
| 3/31/2020 | 88 | -247 | -215 | -212 | N/A |
| 12/31/2019 | 73 | -236 | -241 | -238 | N/A |
| 9/30/2019 | 60 | -221 | -229 | -226 | N/A |
| 6/30/2019 | 60 | -222 | -236 | -230 | N/A |
| 3/31/2019 | 57 | -223 | -250 | -244 | N/A |
| 12/31/2018 | 60 | -216 | -120 | -113 | N/A |
| 9/30/2018 | 49 | -252 | -111 | -105 | N/A |
| 6/30/2018 | 41 | -260 | -123 | -118 | N/A |
| 3/31/2018 | 21 | -285 | N/A | -101 | N/A |
| 12/31/2017 | 15 | -285 | N/A | -201 | N/A |
| 9/30/2017 | 17 | -266 | N/A | -185 | N/A |
| 6/30/2017 | 31 | -233 | N/A | -135 | N/A |
| 3/31/2017 | 33 | -214 | N/A | -123 | N/A |
| 12/31/2016 | 49 | -191 | N/A | -99 | N/A |
| 9/30/2016 | 47 | -168 | N/A | -105 | N/A |
| 6/30/2016 | 38 | -182 | N/A | -124 | N/A |
| 3/31/2016 | 40 | -182 | N/A | -139 | N/A |
| 12/31/2015 | 42 | -182 | N/A | -169 | N/A |
| 9/30/2015 | 40 | -202 | N/A | -178 | N/A |
| 6/30/2015 | 35 | -209 | N/A | -182 | N/A |
| 3/31/2015 | 31 | -219 | N/A | -187 | N/A |
| 12/31/2014 | 12 | -237 | N/A | -175 | N/A |
| 9/30/2014 | 10 | -217 | N/A | -168 | N/A |
| 6/30/2014 | 4 | -203 | N/A | -164 | N/A |
| 3/31/2014 | 1 | -184 | N/A | -137 | N/A |
| 12/31/2013 | 0 | -156 | N/A | -121 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: TBPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Winst versus markt: TBPH is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: TBPH is expected to become profitable in the next 3 years.
Omzet versus markt: TBPH's revenue (18.9% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: TBPH's revenue (18.9% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if TBPH's Return on Equity is forecast to be high in 3 years time